+

WO2005027840A3 - Approches combinees pour produire des reponses immunitaires - Google Patents

Approches combinees pour produire des reponses immunitaires Download PDF

Info

Publication number
WO2005027840A3
WO2005027840A3 PCT/US2004/030233 US2004030233W WO2005027840A3 WO 2005027840 A3 WO2005027840 A3 WO 2005027840A3 US 2004030233 W US2004030233 W US 2004030233W WO 2005027840 A3 WO2005027840 A3 WO 2005027840A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune responses
polypeptides
generating immune
hiv
combination approaches
Prior art date
Application number
PCT/US2004/030233
Other languages
English (en)
Other versions
WO2005027840A2 (fr
Inventor
Victor Raul Gomez-Roman
Susan W Barnett
Ying Lian
Bo Peng
Marjorie Robert-Guroff
Indresh K Srivastava
Original Assignee
Chiron Corp
Us Gov Health & Human Serv
Victor Raul Gomez-Roman
Susan W Barnett
Ying Lian
Bo Peng
Marjorie Robert-Guroff
Indresh K Srivastava
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Us Gov Health & Human Serv, Victor Raul Gomez-Roman, Susan W Barnett, Ying Lian, Bo Peng, Marjorie Robert-Guroff, Indresh K Srivastava filed Critical Chiron Corp
Priority to CA002539021A priority Critical patent/CA2539021A1/fr
Priority to US10/571,882 priority patent/US20070166784A1/en
Priority to EP04788769A priority patent/EP1667631A4/fr
Publication of WO2005027840A2 publication Critical patent/WO2005027840A2/fr
Publication of WO2005027840A3 publication Critical patent/WO2005027840A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés, des polynucléotides et des polypeptides codant des polypeptides immunogènes du VIH dérivés de différentes souches dans un sous-type du VIH et/ou des polypeptides immunogènes du VIH de différents sous-types. L'invention concerne des utilisations des polynucléotides et des polypeptides dans approches combinées pour produire des réponses immunitaires. Ces approches combinées induisent une activité de neutralisation large et puissante contre diverses souches du VIH provenant de multiples souches dans un sous-type données et contre divers sous-types. L'invention concerne enfin des formulations de compositions pour produire des réponses immunitaires ainsi que des procédés d'utilisation de ces compositions.
PCT/US2004/030233 2003-09-15 2004-09-15 Approches combinees pour produire des reponses immunitaires WO2005027840A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002539021A CA2539021A1 (fr) 2003-09-15 2004-09-15 Approches combinees pour produire des reponses immunitaires
US10/571,882 US20070166784A1 (en) 2003-09-15 2004-09-15 Combination approaches for generating immune responses
EP04788769A EP1667631A4 (fr) 2003-09-15 2004-09-15 Approches combinees pour produire des reponses immunitaires

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50361703P 2003-09-15 2003-09-15
US50450103P 2003-09-15 2003-09-15
US60/504,501 2003-09-15
US60/503,617 2003-09-15

Publications (2)

Publication Number Publication Date
WO2005027840A2 WO2005027840A2 (fr) 2005-03-31
WO2005027840A3 true WO2005027840A3 (fr) 2009-04-09

Family

ID=34381080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/030233 WO2005027840A2 (fr) 2003-09-15 2004-09-15 Approches combinees pour produire des reponses immunitaires

Country Status (4)

Country Link
US (1) US20070166784A1 (fr)
EP (1) EP1667631A4 (fr)
CA (1) CA2539021A1 (fr)
WO (1) WO2005027840A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006302794B2 (en) 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
GB2452958A (en) * 2007-09-20 2009-03-25 Glaxosmithkline Biolog Sa HIV vaccine compositions
JP5873717B2 (ja) 2008-04-04 2016-03-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｉｌ−２８及び組成物を用いたワクチン及び免疫治療薬並びにその使用方法
WO2011028963A2 (fr) * 2009-09-03 2011-03-10 Biological Mimetics, Inc. Compositions immunogènes du vih
WO2012159120A2 (fr) * 2011-05-19 2012-11-22 University Of Florida Research Foundation, Inc. Stratégie basée sur la thérapie génique pour traiter l'infection par le vih
WO2012162428A1 (fr) * 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Primovaccination-rappel pour infection virale
SG11201400987QA (en) 2011-09-26 2014-07-30 Theravectys Use of non-subtype b gag proteins for lentiviral packaging
WO2014151687A2 (fr) 2013-03-15 2014-09-25 University Of Massachusetts Compositions et procédés pour traiter le sida
PT3197489T (pt) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana
TWI792091B (zh) 2015-12-15 2023-02-11 荷蘭商傑森疫苗防護公司 人類免疫缺陷病毒抗原、載體、組成物、及其使用方法
SG11201810549TA (en) 2016-06-16 2018-12-28 Janssen Vaccines & Prevention Bv Hiv vaccine formulation
WO2018045267A1 (fr) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Procédés pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets subissant un traitement antirétroviral
HUE052008T2 (hu) 2016-09-15 2021-04-28 Janssen Vaccines & Prevention Bv Trimert stabilizáló HIV-burokfehérje-mutációk
AU2018283811B2 (en) 2017-06-15 2022-10-20 Bavarian Nordic A/S Poxvirus vectors encoding HIV antigens, and methods of use thereof
CA3069052A1 (fr) 2017-07-19 2019-01-24 Janssen Vaccines & Prevention B.V. Mutations de proteine d'enveloppe du vih stabilisant la forme trimere

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6585979B1 (en) * 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
US5840313A (en) * 1990-09-27 1998-11-24 Syntello Vaccine Development Kb Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
CN1111540C (zh) * 1993-06-09 2003-06-18 康诺特实验室有限公司 串联的合成hiv－1肽类
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
ES2299276T3 (es) * 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos env del vih modificados.
EP1980617A1 (fr) * 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Expression améliorée de polypeptides HIV et production de particules de type virus
US7211659B2 (en) * 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
ES2339762T3 (es) * 2002-01-14 2010-05-25 Novartis Vaccines And Diagnostics, Inc. Vacuna contra el vih y procedimiento de uso.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US6585979B1 (en) * 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LJUNGBERG ET AL.: "Enhanced Immune Responses After DNA Vaccination with Combined Envelope Genes from Different HIV-1 Subtypes.", VIROLOGY, vol. 302, no. 12, 2002, pages 44 - 57, XP008107812 *

Also Published As

Publication number Publication date
EP1667631A4 (fr) 2010-04-14
CA2539021A1 (fr) 2005-03-31
WO2005027840A2 (fr) 2005-03-31
EP1667631A2 (fr) 2006-06-14
US20070166784A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
WO2005027840A3 (fr) Approches combinees pour produire des reponses immunitaires
WO2006050394A3 (fr) Approches combinatoires destinees a produire des reponses immunitaires
WO2003004620A3 (fr) Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
WO2004075829A3 (fr) Vaccin contre la grippe contenant un adjuvant
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2006110831A3 (fr) Methode pour induire des anticorps neutralisant le virus de l'immunodeficience humaine
WO2004096818A3 (fr) Procede et compositions pour l'identification de composes therapeutiques anti-vih
WO2002018585A3 (fr) Encapsidation de particules de replicon de virus d'arn a chaine positive
WO2003102166A3 (fr) Nouveaux antigenes de flavivirus
WO2006068663A3 (fr) Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
WO2006026394A3 (fr) Procédé pour provoquer une réponse immunitaire contre le hiv
WO2004096798A3 (fr) Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
PT1411908E (pt) Tratamento de infeccoes da unha com no
WO2006055511A3 (fr) Formule stable de comprimes
EP1129693A3 (fr) Composition pour la prévention des odeurs corporelle et son usage
WO2008098180A3 (fr) Compositions lubrifiantes intimes complémentaires
WO2004033663A3 (fr) Vaccins anti-vih de synthese a base d'hydrates de carbone
WO2009015247A3 (fr) Antigènes vih chimériques
WO2003022869A3 (fr) Mutants de glycoproteines d'enveloppe du vih et leurs utilisations
WO2005039630A3 (fr) Compositions immunogenes
WO2004005476A3 (fr) Compositions d'acide nucleique destinees a stimuler les reponses immunitaires
WO2003051300A8 (fr) Complexes metalliques et formulations d'analogues de rifamycine, utilisations correspondantes
WO2003063851A8 (fr) Composition a usage pharmaceutique ou dietetique pour combatte la chute des cheveux
WO2003066094A3 (fr) Nouveau vaccin
WO2002096936A3 (fr) Daptomycine et analogues s'y rapportant, sous forme cristalline

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480033292.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2539021

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 865/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004788769

Country of ref document: EP

Ref document number: 2006/03029

Country of ref document: ZA

Ref document number: 200603029

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2004788769

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007166784

Country of ref document: US

Ref document number: 10571882

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10571882

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载